181 related articles for article (PubMed ID: 12753398)
1. Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin?
Wankowicz-Kalinska A; Le Poole C; van den Wijngaard R; Storkus WJ; Das PK
Pigment Cell Res; 2003 Jun; 16(3):254-60. PubMed ID: 12753398
[TBL] [Abstract][Full Text] [Related]
2. Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity?
Garbelli S; Mantovani S; Palermo B; Giachino C
Pigment Cell Res; 2005 Aug; 18(4):234-42. PubMed ID: 16029417
[TBL] [Abstract][Full Text] [Related]
3. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells.
Cui J; Bystryn JC
Arch Dermatol; 1995 Mar; 131(3):314-8. PubMed ID: 7887661
[TBL] [Abstract][Full Text] [Related]
4. Immunological basis of melanoma-associated vitiligo-like depigmentation.
González R; Torres-López E
Actas Dermosifiliogr; 2014 Mar; 105(2):122-7. PubMed ID: 23146137
[TBL] [Abstract][Full Text] [Related]
5. The antibody response against MART-1 differs in patients with melanoma-associated leucoderma and vitiligo.
Teulings HE; Willemsen KJ; Glykofridis I; Krebbers G; Komen L; Kroon MW; Kemp EH; Wolkerstorfer A; van der Veen JP; Luiten RM; Tjin EP
Pigment Cell Melanoma Res; 2014 Nov; 27(6):1086-96. PubMed ID: 25043574
[TBL] [Abstract][Full Text] [Related]
6. Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality?
Ram M; Shoenfeld Y
Ann N Y Acad Sci; 2007 Sep; 1110():410-25. PubMed ID: 17911456
[TBL] [Abstract][Full Text] [Related]
7. Antibodies to normal human melanocytes in vitiligo.
Naughton GK; Eisinger M; Bystryn JC
J Exp Med; 1983 Jul; 158(1):246-51. PubMed ID: 6345714
[TBL] [Abstract][Full Text] [Related]
8. Qualitative difference between the cytotoxic T lymphocyte responses to melanocyte antigens in melanoma and vitiligo.
Palermo B; Garbelli S; Mantovani S; Scoccia E; Da Prada GA; Bernabei P; Avanzini MA; Brazzelli V; Borroni G; Giachino C
Eur J Immunol; 2005 Nov; 35(11):3153-62. PubMed ID: 16224813
[TBL] [Abstract][Full Text] [Related]
9. T cell immune responses against melanoma and melanocytes in cancer and autoimmunity.
Kawakami Y; Suzuki Y; Shofuda T; Kiniwa Y; Inozume T; Dan K; Sakurai T; Fujita T
Pigment Cell Res; 2000; 13 Suppl 8():163-9. PubMed ID: 11041376
[TBL] [Abstract][Full Text] [Related]
10. Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation.
Naughton GK; Eisinger M; Bystryn JC
J Invest Dermatol; 1983 Dec; 81(6):540-2. PubMed ID: 6196421
[TBL] [Abstract][Full Text] [Related]
11. [Detection of serum autoantibodies to melanocyte and correlation between melanoma antigen recognized by T-cells and vitiligo in children].
Chen JP; Li HP; Jin SH; Zhang JT; Li J
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Oct; 29(10):2107-8, 2111. PubMed ID: 19861278
[TBL] [Abstract][Full Text] [Related]
12. Tumor antigens isolated from a patient with vitiligo and T-cell-infiltrated melanoma.
Kiniwa Y; Fujita T; Akada M; Ito K; Shofuda T; Suzuki Y; Yamamoto A; Saida T; Kawakami Y
Cancer Res; 2001 Nov; 61(21):7900-7. PubMed ID: 11691810
[TBL] [Abstract][Full Text] [Related]
13. Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo.
Le Gal FA; Avril MF; Bosq J; Lefebvre P; Deschemin JC; Andrieu M; Dore MX; Guillet JG
J Invest Dermatol; 2001 Dec; 117(6):1464-70. PubMed ID: 11886510
[TBL] [Abstract][Full Text] [Related]
14. Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo).
Merimsky O; Shoenfeld Y; Baharav E; Zigelman R; Fishman P
Hum Antibodies Hybridomas; 1996; 7(4):151-6. PubMed ID: 9140726
[TBL] [Abstract][Full Text] [Related]
15. A symbiotic concept of autoimmunity and tumour immunity: lessons from vitiligo.
Das PK; van den Wijngaard RM; Wankowicz-Kalinska A; Le Poole IC
Trends Immunol; 2001 Mar; 22(3):130-6. PubMed ID: 11286727
[TBL] [Abstract][Full Text] [Related]
16. Molecular and cellular basis of depigmentation in vitiligo patients.
Delmas V; Larue L
Exp Dermatol; 2019 Jun; 28(6):662-666. PubMed ID: 30536790
[TBL] [Abstract][Full Text] [Related]
17. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo.
Uchi H; Stan R; Turk MJ; Engelhorn ME; Rizzuto GA; Goldberg SM; Wolchok JD; Houghton AN
Adv Immunol; 2006; 90():215-41. PubMed ID: 16730265
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic implications of autoimmune vitiligo T cells.
Oyarbide-Valencia K; van den Boorn JG; Denman CJ; Li M; Carlson JM; Hernandez C; Nishimura MI; Das PK; Luiten RM; Le Poole IC
Autoimmun Rev; 2006 Aug; 5(7):486-92. PubMed ID: 16920575
[TBL] [Abstract][Full Text] [Related]
19. IgG anti-melanocyte antibodies purified from patients with active vitiligo induce HLA-DR and intercellular adhesion molecule-1 expression and an increase in interleukin-8 release by melanocytes.
Li YL; Yu CL; Yu HS
J Invest Dermatol; 2000 Dec; 115(6):969-73. PubMed ID: 11121127
[TBL] [Abstract][Full Text] [Related]
20. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy.
Okamoto T; Irie RF; Fujii S; Huang SK; Nizze AJ; Morton DL; Hoon DS
J Invest Dermatol; 1998 Dec; 111(6):1034-9. PubMed ID: 9856813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
